Clofazimine, Psora-4 and PAP-1, inhibitors of the potassium channel Kv1.3, as a new and selective therapeutic strategy in chronic lymphocytic leukemia

Leukemia

Volumn 27, Issue 8, 2013, Pages 1782-1785

  Leanza, L ^a   Trentin, L ^a   Becker, K A ^b   Frezzato, F ^a   Zoratti, M ^a   Semenzato, G ^a   Gulbins, E ^b   Szabo, I ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; PAP 1,; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.3; PSORA 4; UNCLASSIFIED DRUG;

APOPTOSIS; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CELL FRACTIONATION; CHROMOSOME ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LETTER; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CLOFAZIMINE; FICUSIN; HUMANS; KV1.3 POTASSIUM CHANNEL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; POTASSIUM CHANNEL BLOCKERS;

EID: 84881479922     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.56     Document Type: Letter

References (16)

1. D'Amico M, Gasparoli L, Arcangeli A. Potassium channels: novel emerging bio-markers and targets for therapy in cancer. Recent Pat Anticancer Drug Discov 2013; 8: 53-65.
2. + channels in neoplastic hematopoietic cells. J Biol Chem 2002; 277: 18528-18534. (Pubitemid 34952403)
3. Cahalan MD, Chandy KG. The functional network of ion channels in T lymphocytes. Immunol Rev 2009; 231: 59-87.
4. Szabo I, Leanza L, Gulbins E, Zoratti M. Physiology of potassium channels in the inner membrane of mitochondria. Pflugers Arch 2012; 463: 231-246.
5. Leanza L, Henry B, Sassi N, Zoratti M, Chandy KG, Gulbins E et al. Inhibitors of mitochondrial Kv1.3 channels induce Bax/Bak-independent death of cancer cells. EMBO Mol Med 2012; 4: 577-593.
6. Gulbins E, Sassi N, Grassmè H, Zoratti M, Szabò I. Role of Kv1.3 mitochondrial potassium channel in apoptotic signalling in lymphocytes. Biochim Biophys Acta 2010; 1797: 1251-1259.
7. Szabó I, Bock J, Grassmé H, Soddemann M, Wilker B, Lang F et al. Mitochondrial potassium channel Kv1.3 mediates Bax-induced apoptosis in lymphocytes. Proc Natl Acad Sci USA 2008; 105: 14861-14866.
8. L expressed in Bax-and Bak-less mouse embryonic fibroblasts: novel insights into the molecular mechanisms of Bax-induced apoptosis. Cell Death Differ 2011; 18: 427-438.
9. Cerutti A, Trentin L, Zambello R, Sancetta R, Milani A, Tassinari C et al. The CD5/CD72 receptor system is coexpressed with several functionally relevant coun-terstructures on human B cells and delivers a critical signaling activity. J Immunol 1996; 157: 1854-1862. (Pubitemid 126449656)
10. Van Rensburg CE, Jooné G, Anderson R. Alpha-tocopherol antagonizes the mul-tidrug-resistance-reversal activity of cyclosporin A, verapamil, GF120918, clofazi-mine and B669. Cancer Lett 1998; 127: 107-112. (Pubitemid 28230792)
11. Trentin L, Cabrelle A, Facco M, Carollo D, Miorin M, Tosoni A et al. Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood 2004; 104: 502-508. (Pubitemid 38900034)
12. Ralph SJ, Rodríguez-Enríquez S, Neuzil J, Moreno-Sánchez R. Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol Aspects Med 2010; 31: 29-59.
13. Sassi N, Biasutto L, Mattarei A, Carraro M, Giorgio V, Citta A et al. Cytotoxicity of a mitochondriotropic quercetin derivative: mechanisms. Biochim Biophys Acta 2012; 1817: 1095-1106.
14. 2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem J 2009; 418: 29-37.
15. Klein U, Dalla-Favera R. New insights into the phenotype and cell derivation of B cell chronic lymphocytic leukemia. Curr Top Microbiol Immunol 2005; 294: 31-49. (Pubitemid 41491249)
16. Cholo MC, Steel HC, Fourie PB, Germishuizen WA, Anderson R. Clofazimine: current status and future prospects. J Antimicrob Chemother 2012; 67: 290-298.